In the News

Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEsFIERCE BIOTECH, 10/14/26

Research and Discovery Oncology

Vir makes solid tumor T cell engager deal with GileadENDPOINTS, 10/14/26

Research and Discovery Artificial Intelligence Oncology

Tobevibart Combo Shows High Hepatitis D Efficacy: Tarik Asselah, MD, PhDAJMC, 8/12/26

Chronic Hepatitis Delta

BIO 2026: Vir is scheduled to have its first phase 3 readout in Hepatitis Delta before the end of the year - they believe that their dual mechanism is the difference maker hereBIOTECHTV, 6/24/26

Chronic Hepatitis Delta Oncology

ASCO 2026: Vir Biotechnology CEO Marianne De Backer discusses the company's masked T-cell engager platform, which recently earned the company a partnership with Astellas on PSMABIOTECHTV, 5/30/26

Research and Discovery Oncology

Tobevibart-Elebsiran Sustains HDV Suppression at 96 Weeks.Tarik Asselah, MD, PhDAJMC, 5/29/26

Chronic Hepatitis Delta

How Marianne De Backer (Vir Bio) saved Vir after flu drug failureSFBT, 5/15/26

Oncology

Vir Biotechnology Rings the Nasdaq Stock Market Closing BellNasdaq, 4/14/26

Research and Discovery Oncology

As Vir validates bispecific masking hypothesis, Astellas buys inBioCentury, 3/4/26

Oncology

Researchers praise ‘stunning’ results of new prostate cancer treatmentThe Guardian, 2/28/26

Oncology

Astellas Bets up to $1.7B for Vir’s ‘Robust Competitor’ in Prostate CancerBioSpace, 2/24/26

Oncology

How a prostate cancer drug and a $1.7 billion deal landed at Vir BioSFBT, 2/24/26

Oncology

‘The perfect partner’ Astellas, Vir engage in $1.7B dealFierce Biotech, 2/23/26

Oncology

Astellas pays $240M cash for Vir's prostate cancer drugEndpoints, 2/23/26

Oncology